The addition of capecitabine to trastuzumab emtansine does not improve the clinical outcomes of patients with previously treated HER2-positive metastatic breast cancer, indicates the phase 1/2 TRAXHER2 study.
Women with interval breast cancers diagnosed within 1 year of a negative mammogram screening result have poorer disease-specific survival than those with screen-detected cancers, US study findings indicate.
Women with breast cancer had higher than normal levels of severe anxiety, depression, distress, and insomnia at the peak of the COVID-19 outbreak in the Hubei Province in China, study findings indicate.
Combining pyrotinib instead of lapatinib with capecitabine is associated with significantly improved progression-free survival in patients who have received prior treatment for HER2-positive metastatic breast cancer, show phase 3 trial data.
Individuals who present with metastatic breast cancer do not experience improvement in overall survival or other outcomes with early locoregional therapy for an intact primary tumor, according to ECOG-ACRIN 2108 trial findings.
Adjuvant treatment with trastuzumab emtansine does not improve outcome or reduce toxicity relative to that with a taxane plus trastuzumab in patients with HER2-positive early breast cancer, results of the phase 3 KAITLIN study show.
Long-term follow-up of the TRAIN-2 study shows that patients with stage II or III HER2-positive breast cancer who receive neoadjuvant chemotherapy and dual HER2-blockade derive no survival benefit from the addition of anthracyclines.
The combination of alpelisib and fulvestrant could be a promising option for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment, indicate trial data.
Tucatinib, a selective HER2 kinase inhibitor, added to trastuzumab and capecitabine has demonstrated a survival benefit in patients with HER2-positive breast cancer and brain metastases in the HER2CLIMB trial, as presented at the virtual 2020 ASCO Annual Meeting.
A phase 3 trial has failed to demonstrate the noninferiority of delayed targeted intraoperative radiotherapy to whole-breast external beam radiotherapy in terms of local control at 5 years in patients with early-stage breast cancer, but other long-term outcomes were comparable.
Women with hormone receptor-positive, HER2-positive locally advanced, metastatic, or recurrent breast cancer might benefit from a third- or later-line regimen of the CDK4/6 inhibitor abemaciclib in combination with trastuzumab and fulvestrant, findings from the phase 2 monarcHER trial suggests.
Chemotherapy may only offer additional overall survival benefit over endocrine therapy alone for women with hormone receptor-positive, HER2-positive breast cancer size of 8–10 mm and not those with smaller tumors, report US researchers in a letter to JAMA Network Open